GeNeuro’s temelimab shows extended neuroprotective effects in relapsing-remitting MS
- Further evidence adds to already strong set of positive clinical data
- Data presented at ECTRIMS 2019 Congress in Stockholm, Sweden
Geneva, Switzerland, September 16, 2019 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS) and type-1 diabetes (T1D), today announced that the neuroprotective effects of temelimab in MS patients extend to 96 weeks and that it is safe to use and well tolerated for a prolonged period. These data, from ANGEL-MS, an extension of the Phase 2 CHANGE-MS trial in relapsing-remitting MS (RRMS), were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2019) Congress in Stockholm, Sweden.
For more information, https://www.geneuro.com/data/news/GeNeuro-ECTRIMS-PR-160919-ENG.pdf